Tag Archives: Edward Miller

GrowPros

Tetra Bio-Pharma to Attend the 10th Annual International Partnering Conference – BioPharm America

Tetra Bio-Pharma to Attend the 10th Annual International Partnering Conference – BioPharm America

OTTAWA, Ontario, Sept. 8, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that its Vice President of Business Development, Mr. Bob Bechard, is scheduled to attend the 10th Annual International Partnering Conference, BioPharm America, September 26-27 at the Sheraton Boston Hotel.

GrowPros

Tetra Bio-Pharma to Benefit from Intellectual Properties Created within the Cannabis Health Research Chair from the University of New Brunswick

OTTAWA, Ontario, Aug. 31, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that it will benefit from the intellectual property (IP) created within the cannabis health research Chair (The Chair) from the University of New Brunswick (UNB).

GrowPros

Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange

OTTAWA, Ontario, Aug. 16, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (” Tetra ” or the ” Company “) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE).

Appointments Constance Therapeutics Bernard Fortier

Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO

OTTAWA, Ontario July 24, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017.

Appointments Constance Therapeutics Bernard Fortier

Tetra Bio-Pharma Signs Letter of Intent with Constance Therapeutics

OTTAWA, Ontario, July 19, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.

Tetra Bio-Pharma Its Position

Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders’ Meeting & Provides a Corporate Update

OTTAWA, Ontario, July 11, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), is pleased to announce the results of the vote at its July 10, 2017 annual shareholders’ meeting.

Tetra Bio-Pharma Its Position

Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals

OTTAWA, Ontario, July 5, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug.


Top